These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34850298)

  • 21. Analytic characterization of biosimilars.
    Sullivan PM; DiGrazia LM
    Am J Health Syst Pharm; 2017 Apr; 74(8):568-579. PubMed ID: 28389456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.
    Waller CF; Tiessen RG; Lawrence TE; Shaw A; Liu MS; Sharma R; Baczkowski M; Kothekar MA; Micales CE; Barve A; Ranganna GM; Pennella EJ
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1087-1095. PubMed ID: 29671069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Analysis of Biosimilar Switching Studies.
    Chow SC; Lee SJ
    Pharmaceut Med; 2019 Oct; 33(5):379-388. PubMed ID: 31933227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
    Araújo F; Cordeiro I; Teixeira F; Gonçalves J; Fonseca JE
    Acta Reumatol Port; 2014; 39(1):19-26. PubMed ID: 24811458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis.
    Burmester G; Chien D; Chow V; Gessner M; Pan J; Cohen S
    Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1003-1014. PubMed ID: 32627420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioequivalence of a biosimilar enoxaparin sodium to Clexane
    Martínez González J; Monreal M; Ayani Almagia I; Llaudó Garín J; Ochoa Díaz de Monasterioguren L; Gutierro Adúriz I
    Drug Des Devel Ther; 2018; 12():575-582. PubMed ID: 29593380
    [TBL] [Abstract][Full Text] [Related]  

  • 27. On sample size requirement for analytical similarity assessment.
    Zhao Y; Chang YW; Chow SC
    J Biopharm Stat; 2018; 28(6):1143-1159. PubMed ID: 29513612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
    Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
    BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical trials for authorized biosimilars in the European Union: a systematic review.
    Mielke J; Jilma B; Koenig F; Jones B
    Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Simulation Approach to Evaluate the Impact of Patterns of Bioanalytical Bias Difference on the Outcome of Pharmacokinetic Similarity Studies.
    Obianom ON; Okusanya OO; Earp J; Thway TM
    Clin Pharmacol Ther; 2020 Jul; 108(1):107-115. PubMed ID: 31957006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bridging bioequivalence studies.
    Liu JP
    J Biopharm Stat; 2004 Nov; 14(4):857-67. PubMed ID: 15587968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bias of two one-sided tests procedures in assessment of bioequivalence.
    Liu JP; Weng CS
    Stat Med; 1995 Apr; 14(8):853-61. PubMed ID: 7644864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size determination for individual bioequivalence inference.
    Chiang C; Hsiao CF; Liu JP
    PLoS One; 2014; 9(10):e109746. PubMed ID: 25310592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-Based Approach to Selecting Pegfilgrastim Dose for Pharmacokinetic and Pharmacodynamic Similarity Studies in Biosimilar Development.
    Li F; Sun Q; Du S; Florian J; Wang Y; Huang SM; Zineh I; Wang YC
    Clin Pharmacol Ther; 2023 Jan; 113(1):62-70. PubMed ID: 36000498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On assessment of bioequivalence under a higher-order crossover design.
    Chow SC; Liu JP
    J Biopharm Stat; 1992; 2(2):239-56. PubMed ID: 1300216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robustness of bioequivalence procedures under Box-Cox alternatives.
    Xiao W; Barron AM; Liu J
    J Biopharm Stat; 1997 Mar; 7(1):135-55. PubMed ID: 9056594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BOB: Bayesian optimal design for biosimilar trials with co-primary endpoints.
    Chi X; Yu Z; Lin R
    Stat Med; 2022 Nov; 41(26):5319-5334. PubMed ID: 36127794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
    Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
    Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.